Sites, Selectivity, and Petrelintide Positioning
Week Of April 18 – April 24, 2026
Five big cardiometabolic trials added around 500 new clinical sites to ClinicalTrials.gov in a single week. Pfizer’s MET097 VESPER-4 added 191, Lilly’s orforglipron ATTAIN-Outcomes added 151, and Amgen’s MARITIME-CV added 119. That seemed notable this week, and I go into what it means in the Trial Spotlight. The Mechanism Explained is on amycretin, prompted partly by a new Novo Phase 1 mechanism study this week. If you’ve wondered what makes amycretin different from CagriSema, and why the amylin drugs are splitting into selective and non-selective camps, check out that part of the newsletter.
Separately, Novo’s oral semaglutide met its Phase 3 endpoint in adolescents with T2D (PIONEER TEENS). CMS (Centers for Medicare & Medicaid Services) delayed its Part D GLP-1 pilot to 2027 after insurers declined to participate. Roche used its Q1 earnings to reframe petrelintide as a tolerability-first option rather than a direct competitor to tirzepatide, which is more of a positioning shift than new data since the Phase 2 results were released in March. And Novo’s Phase 3 CagriSema vs tirzepatide trial in T2D (NCT06221969) completed this week, the T2D counterpart to February’s REDEFINE 4 obesity trial where CagriSema missed non-inferiority. The readout is one to watch.
🔥 THIS WEEK’S KEY DEVELOPMENTS
Roche CEO reframes petrelintide as a tolerability-first amylin at Q1 earnings.
In Q1 2026 earnings commentary, Roche CEO Thomas Schinecker positioned petrelintide (its long-acting amylin analog co-developed with Zealand Pharma) as a high-tolerability alternative for maintenance use and for patients who cannot tolerate incretin-based therapies, rather than as a head-to-head competitor to GLP-1/GIP dual agonists on efficacy. The underlying Phase 2 ZUPREME-1 data (up to 10.7% weight loss at week 42 with placebo-like tolerability) was originally reported in March, so the new element is the positioning rather than the data.
BioSpace context | Mechanism: amylin analog (AMYR + CTR agonist)
Oral semaglutide meets Phase 3 endpoint in adolescents with type 2 diabetes.
Novo Nordisk announced positive topline results from the PIONEER TEENS Phase 3a trial evaluating oral semaglutide in children and adolescents aged 10-17 with type 2 diabetes. The trial met its primary endpoint with a statistically significant 0.83% HbA1c reduction vs placebo at 26 weeks. Novo plans to file for a label expansion in the US and EU in the second half of 2026, positioning oral semaglutide as potentially the first oral GLP-1 RA approved for this pediatric population.
Press | Trials: NCT04596631 | Mechanism: oral GLP-1 receptor agonist
CMS delays Part D GLP-1 pilot (BALANCE) to 2027 after insurers refuse to participate.
The Centers for Medicare and Medicaid Services has indefinitely postponed its BALANCE financing model for Medicare Part D, which was designed to make GLP-1 weight-loss drugs more affordable for seniors. Insurers including CVS and UnitedHealth declined to participate, citing concerns about financial risk and lack of utilization data. CMS will continue the parallel Medicaid program and extend a bridge model to maintain interim beneficiary access. Lilly and Novo Nordisk stocks dipped on the news given the potential revenue impact.
BioSpace | FiercePharma | Mechanism: policy
📰 PRESS
FDA issues warning letter after a GLP-1 manufacturer refuses inspectors access to its facility.
FDA letter (New Life Pharma) | BioSpace | Mechanism: regulatory / manufacturing
Roche CEO outlines why the company is sitting out the current Big Pharma M&A wave, citing enicepatide and petrelintide as internal growth drivers.
FierceBiotech | Mechanism: strategy
Altimmune prices $225 million public offering to fund Phase 3 MASH trial of pemvidutide.
Altimmune IR | Mechanism: GLP-1 / glucagon dual agonist
Oral GLP-1 tracker: Lilly’s Foundayo launch continues to trail Novo’s Wegovy pill in early scripts.
FiercePharma | Mechanism: oral GLP-1
💡 TRIAL SPOTLIGHT
Educational spotlight selected by editors
The Phase 3 Geographic Arms Race: 500 Sites Added in a Week Across MET097, Orforglipron, and MariTide CVOTs
Between April 18 and 24, 2026, five late-stage cardiometabolic trials added approximately 500 new clinical sites to their ClinicalTrials.gov registrations. The timing signals that the post-Foundayo obesity race has moved from pipeline dealmaking into operational execution. New-site postings lag actual activations by a few weeks, but a surge of this magnitude reflects real, committed infrastructure coming online. The ramp was led by Pfizer’s VESPER-4 obesity trial for MET097, an ultra-long-acting, fully-biased GLP-1 mono-agonist, which added 191 locations (n=3,500, primary completion September 2027) just as its Phase 2 wrapped the same week. Eli Lilly’s ATTAIN-Outcomes trial followed with 151 new sites (n=7,140, primary completion August 2031), pursuing ASCVD and chronic kidney disease label expansions for its newly approved oral Foundayo (orforglipron). Amgen’s MARITIME-CV activated 119 sites for maridebart cafraglutide (MariTide), its GLP-1 agonist / GIP antagonist antibody-peptide conjugate; at 12,800 patients it is the largest of the three.
This rapid mobilization is not isolated to cardiovascular outcomes; Lilly concurrently expanded its 4,500-patient SYNERGY-Outcomes MASLD master protocol by 89 sites while scaling its Phase 3 eloralintide programs across sleep apnea and osteoarthritis. What makes this operational footprint strategically vital is the evolving biology of incretins: because GLP-1 effects on MACE, heart failure, and renal decline extend beyond mere weight loss to systemic improvements in inflammation and vascular function, broad cardiometabolic labeling requires massive, multi-year outcomes trials. With Foundayo’s approval proving that the industry has successfully developed the requisite next-generation molecules, the new competitive moat in obesity is sheer infrastructure. The clinical site footprint is now the ultimate proxy for execution, determining whether a company can recruit and run a 12,000-patient trial faster than its peers to capture critical label expansions.
ClinicalTrials.gov: NCT07311850 (VESPER-4, MET097) | NCT07241390 (ATTAIN-Outcomes, orforglipron) | NCT07037433 (MARITIME-CV, maridebart cafraglutide) | NCT07165028 (SYNERGY-Outcomes MASLD)
🔬 MECHANISM EXPLAINED
Understanding the science behind the therapeutics
Amycretin and the Amylin Selectivity Problem (Example drugs: Amycretin, Cagrilintide, Eloralintide, Petrelintide)
Novo Nordisk’s aggressive clinical strategy for amycretin, underscored this week by a new Phase 1 study on insulin regulation (NCT07535307), forces a closer look at the increasingly complex “GLP-1 plus amylin” landscape. Amycretin’s core distinction is its structure: it is a single, unimolecular co-agonist engineered to activate both GLP-1 and amylin receptors. This contrasts sharply with Novo’s other late-stage combination, CagriSema, which is a co-formulation of two separate drugs: the GLP-1 agonist semaglutide and the amylin analog cagrilintide. The unimolecular design offers a unified pharmacokinetic profile and manufacturing simplicity but locks the ratio of GLP-1 to amylin activity. The new mechanism study likely aims to dissect the amylin component’s specific contribution to restoring normal postprandial glucagon suppression, a key physiological role of amylin that is impaired in type 2 diabetes.
This structural choice occurs against a backdrop of active debate over amylin pharmacology itself, centered on receptor selectivity. Native amylin acts on both the amylin receptor (AMYR) and the calcitonin receptor (CTR). While AMYR activation drives the desired effects of satiety and slowed gastric emptying, CTR activation is linked to dose-limiting nausea. This has split the field: some companies are developing dual amylin and calcitonin receptor agonists (DACRAs), like Novo’s cagrilintide, Zealand/Roche’s petrelintide, and AbbVie’s GUB014295 (ABBV-295), betting that broad agonism is optimal. Others are engineering selective amylin receptor agonists (SARAs) to isolate the benefits while minimizing side effects, a strategy pursued by Eli Lilly with eloralintide and AstraZeneca with AZD6234. Ascletis has added a third axis of differentiation with ASC39, an oral small-molecule amylin agonist being co-developed alongside its oral GLP-1 ASC30. Amycretin’s unique unimolecular GLP-1/amylin profile represents yet another largely uncharted path. Novo’s decision to run four Phase 3 trials and at least two parallel Phase 1 mechanism studies reflects the high stakes and scientific uncertainty of pioneering a class where the fundamental rules of pharmacology are still being explored.
ClinicalTrials.gov: NCT07535307 (NNC0487-0111 insulin PoC) | NCT07533175 (AMAZE 2, T2D) | NCT07503210 (AMAZE 12, maintenance) | NCT07508020 (appetite/food intake PoC) | NCT07353931 (Eloralintide OA knee pain)
🆕 NEWLY REGISTERED TRIALS (2 in last week)
HRS9531 Phase 1 evaluating pharmacokinetics in participants with mild to moderate hepatic impairment compared to normal hepatic function (Fujian Shengdi Pharmaceutical / Hengrui; licensed to Kailera as KAI-9531, n=24)
[Safety/Tolerability]
Trials: NCT07540754 | Mechanism: GLP-1/GIP dual agonist
DWRX5003 Phase 1 first-in-human study assessing safety and bioavailability of a semaglutide microneedle patch relative to two other formulations in healthy adults (Daewoong Pharmaceutical, n=72)
[Safety/Tolerability | Novel Delivery]
Trials: NCT07539415 | Mechanism: GLP-1 receptor agonist (microneedle patch formulation)
This newsletter compiles publicly available information from press releases, news sources, and trial registries. Not investment advice.
Get in touch: Reply to this email, leave a comment on the post, or find me on X @GLP1observer. Explore the GLP-1 dashboard at glp1.bio1up.com.